$280.09
2.03% day before yesterday
NYSE, Sep 12, 10:00 pm CET

Bio-Rad Laboratories, Inc. Class B Stock price

$280.34
+5.58 2.03% 1M
+29.19 11.62% 6M
-48.17 14.66% YTD
-41.59 12.92% 1Y
-232.45 45.33% 3Y
-228.50 44.91% 5Y
+142.45 103.31% 10Y
+225.21 408.51% 20Y
NYSE, Closing price Fri, Sep 12 2025
-5.56 1.94%

Key metrics

Basic
Market capitalization
$7.6b
Enterprise Value
$7.4b
Net debt
positive
Cash
$1.4b
Shares outstanding
27.1m
Valuation (TTM | estimate)
P/E
23.9 | 28.8
P/S
3.0 | 2.9
EV/Sales
2.9 | 2.8
EV/FCF
21.3
P/B
1.1
Financial Health
Equity Ratio
70.2%
Return on Equity
-28.1%
ROCE
3.0%
ROIC
2.4%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$2.6b | $2.6b
EBITDA
- | $449.8m
EBIT
$288.7m | $307.5m
Net Income
$319.0m | $263.7m
Free Cash Flow
$347.5m
Growth (TTM | estimate)
Revenue
-0.3% | 2.1%
EBITDA
- | 49.0%
EBIT
-15.5% | 3.0%
Net Income
124.1% | 114.3%
Free Cash Flow
95.8%
Margin (TTM | estimate)
Gross
53.0%
EBITDA
- | 17.2%
EBIT
11.3%
Net
12.5% | 10.1%
Free Cash Flow
13.6%
More
EPS
$11.7
FCF per Share
$12.8
Short interest
5.2%
Employees
8k
Rev per Employee
$330.0k
Show more

Is Bio-Rad Laboratories, Inc. Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Bio-Rad Laboratories, Inc. Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:

Buy
73%
Hold
27%

Financial data from Bio-Rad Laboratories, Inc. Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,554 2,554
0% 0%
100%
- Direct Costs 1,201 1,201
2% 2%
47%
1,354 1,354
2% 2%
53%
- Selling and Administrative Expenses 803 803
1% 1%
31%
- Research and Development Expense 262 262
14% 14%
10%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 289 289
15% 15%
11%
Net Profit 319 319
124% 124%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Rad Laboratories, Inc. Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Rad Laboratories, Inc. Class B Stock News

Neutral
GlobeNewsWire
9 days ago
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys' completion of acquisition of business assets from ReShape Lifesciences, a weight loss and metabolic health solutions, and its official rebrandin...
Neutral
Seeking Alpha
9 days ago
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Good afternoon. Welcome to the Wells Fa...
Neutral
Business Wire
20 days ago
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the company's executive leadership team will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Format: Fireside chat and one-on-one investor meetings Parti...
More Bio-Rad Laboratories, Inc. Class B News

Company Profile

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Head office United States
CEO Norman Schwartz
Employees 7,700
Founded 1952
Website www.bio-rad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today